New updates have been reported about Biocon Biologics (PC:BICON)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biocon Biologics Ltd. has reached a settlement and licensing agreement with Amgen Inc., allowing the company to launch its denosumab biosimilars, Bosaya™ and Aukelso™, in the United States starting October 1, 2025. These biosimilars are equivalent to Amgen’s Prolia® and Xgeva®, used for treating osteoporosis and cancer-related bone conditions. The agreement resolves ongoing patent litigation, enabling Biocon Biologics to expand its oncology and bone health portfolio in the U.S. market.
The U.S. FDA approved both Bosaya™ and Aukelso™ in September 2025, also granting them provisional interchangeability status. Bosaya™ is approved for various osteoporosis-related treatments, while Aukelso™ targets skeletal-related events in cancer patients. This strategic move not only reinforces Biocon Biologics’ position as a global leader in biosimilars but also broadens access to critical biologic therapies. CEO Shreehas Tambe emphasized the importance of this development in enhancing patient access to advanced biologic medicines. The launch marks a significant milestone for Biocon Biologics as it continues to leverage its capabilities to serve patients across multiple therapeutic areas.